Per the CRL, the FDA sought "limited" additional information on the Chemistry Manufacturing and Controls (CMC), which is part of the BLA submission. The goal of CMC is to ensure that every batch of ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second quarter 2024 investor letter. A ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

Agios Pharmaceuticals, Inc. AGIO announced that the FDA has granted orphan drug designation to its novel pyruvate kinase (PK) ...

Shares of Rocket Pharmaceuticals RCKT have plunged 32.9% in the past six months compared with the industry’s decline of 3.4%.

Rocket Pharmaceuticals announced enrollment completion for phase 2 study using its gene therapy RP-A501 for treatment of male ...

Ketosis is a natural metabolic state that is generally safe, but some aspects of it may be dangerous. Popularized by the keto ...

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Examples of these include the use of radioactivity (for example, 33 P) or the reliance upon a secondary enzyme (such as luciferase, peroxidase or pyruvate kinase) for detection. With radioactive ...

Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel ...

Proliferating cells, in particular tumor cells, are characterized by a high amount of the dimeric form of the pyruvate kinase isoenzyme type M2 (Tumor M2-PK). Tumor M2-PK can be determined in EDTA ...